Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Innovent's IBI363 Plus Bevacizumab Cuts Progression or Death Risk 60% in Phase 1b Lung Cancer Trial

By Public Technologies
  • Innovent Biologics announced Oct. 25, 2026, that Phase 1b results for IBI363/TAK-928, jointly developed with Takeda, were presented at ESMO.
  • In immunotherapy-resistant lung adenocarcinoma, IBI363/TAK-928 combined with bevacizumab significantly reduced disease progression or death risk versus docetaxel; overall survival remained immature.
  • First-line chemotherapy combinations showed antitumor activity in lung cancer with low or negative PD-L1 expression and HER2-negative gastric or gastroesophageal junction cancer.
  • Safety remained manageable across the studies, with no new safety signals identified.
  • A global Phase 3 monotherapy trial remains underway; first-line randomized testing is ongoing in lung cancer and planned for gastric cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610252000PR_NEWS_USPR_____CN80403) on October 26, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.